0001104659-24-008327.txt : 20240130
0001104659-24-008327.hdr.sgml : 20240130
20240130170313
ACCESSION NUMBER: 0001104659-24-008327
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240126
FILED AS OF DATE: 20240130
DATE AS OF CHANGE: 20240130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morabito Christopher
CENTRAL INDEX KEY: 0001859284
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37467
FILM NUMBER: 24579051
MAIL ADDRESS:
STREET 1: C/O FULCRUM THERAPEUTICS, INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Astria Therapeutics, Inc.
CENTRAL INDEX KEY: 0001454789
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 STATE STREET
STREET 2: SUITE 1400
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 617-349-1971
MAIL ADDRESS:
STREET 1: 75 STATE STREET
STREET 2: SUITE 1400
CITY: BOSTON
STATE: MA
ZIP: 02109
FORMER COMPANY:
FORMER CONFORMED NAME: CATABASIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20090127
4
1
tm244587-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-26
0
0001454789
Astria Therapeutics, Inc.
ATXS
0001859284
Morabito Christopher
C/O ASTRIA THERAPEUTICS, INC.
75 STATE STREET, SUITE 1400
BOSTON
MA
02109
0
1
0
0
Chief Medical Officer
1
Common Stock
2024-01-26
4
M
0
800
3.87
A
800
D
Common Stock
2024-01-26
4
S
0
800
11.015
D
0
D
Common Stock
2024-01-29
4
M
0
9200
3.87
A
9200
D
Common Stock
2024-01-29
4
S
0
9200
11.1470
D
0
D
Stock Option (Right to Buy)
3.87
2024-01-26
4
M
0
800
0
D
2032-07-31
Common Stock
800
99200
D
Stock Option (Right to Buy)
3.87
2024-01-29
4
M
0
9200
0
D
2032-07-31
Common Stock
9200
90000
D
This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.02, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
/s/ Ben Harshbarger, as attorney-in-fact for Christopher Morabito
2024-01-30